A first-of-its-kind clinical trial has revealed that a special class of long-lived immune cells could make cancer treatment more effective and less toxic. Researchers enhanced CAR-T cell therapy by enriching it with stem-cell-like T cells, which persist longer and attack tumors more efficiently.
In the study, 5 out of 11 patients with difficult blood cancers achieved full remission — a significant improvement over standard approaches. The treatment also worked at lower doses with milder side effects.
While larger trials are needed, this innovation marks a promising step toward more powerful and personalized cancer immunotherapies in the future.
Read more at Nature